Erste Group Bank Has Weak Forecast for NVO FY2026 Earnings

Novo Nordisk A/S (NYSE:NVO) – Stock analysts at Erste Group Bank reduced their FY2026 earnings per share (EPS) estimates for Novo Nordisk A/S in a research report issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $3.22 per share for the year, down from their previous forecast of $3.23. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.38 per share.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter.

Several other equities research analysts have also issued reports on NVO. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Finally, HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Five analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $50.29 on Friday. The stock has a market cap of $224.56 billion, a PE ratio of 11.81, a P/E/G ratio of 4.70 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The business’s 50-day moving average price is $46.09 and its two-hundred day moving average price is $45.83.

Institutional Trading of Novo Nordisk A/S

Institutional investors and hedge funds have recently bought and sold shares of the stock. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $25,000. Scarborough Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $26,000. WealthCollab LLC raised its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $28,000. Finally, Maseco LLP acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $29,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
• Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
• Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
• Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
• Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.